SMC2 as a potential prognostic biomarker in lung adenocarcinoma and its correlation with immune microenvironment
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Structural maintenance of chromosome 2 (SMC2) is highly expressed in lung adenocarcinoma (LUAD), correlating with poor prognosis and immune suppression. Targeting SMC2 may improve LUAD treatment outcomes.
Area Of Science
- Oncology
- Molecular Biology
Background
- Structural maintenance of chromosome 2 (SMC2) is implicated in various cancers.
- Its specific role in lung adenocarcinoma (LUAD) requires further elucidation.
Purpose Of The Study
- To investigate the expression, prognostic significance, and immune-related functions of SMC2 in LUAD.
- To explore SMC2 as a potential therapeutic target for LUAD.
Main Methods
- Bioinformatic analysis using TCGA, TIMER 2.0, TISIDB, cBioportal, GO, GSEA, KEGG.
- Quantitative PCR and immunohistochemistry on LUAD tissues.
- Clinical data analysis of 70 LUAD patients.
Main Results
- SMC2 was significantly upregulated in LUAD tissues and cell lines, linked to adverse clinicopathological features and poor prognosis.
- SMC2 expression correlated with cell cycle regulation and suppressive immune cells (e.g., B cells) in LUAD.
- High SMC2 expression was associated with immunosuppressive genes, poor response to immunotherapy, and potentially promotes LUAD progression.
Conclusions
- SMC2 is a potential biomarker for poor prognosis in LUAD.
- SMC2 may play a role in immune evasion and malignant progression of LUAD.
- Targeting SMC2 could offer a novel therapeutic strategy for improving LUAD patient outcomes.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.